Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition
Johnson & Johnson (NYSE: JNJ) has announced plans to complete its acquisition of Intra-Cellular Therapies around April 2, 2025, following shareholder approval on March 27, 2025. The transaction is projected to boost JNJ's 2025 sales growth by 0.8%, adding approximately $0.7 billion in incremental sales.
The acquisition is expected to dilute adjusted earnings per share (EPS) by $0.25 in 2025, an improvement from the previously estimated $0.30-$0.35 dilution. For 2026, earnings dilution is anticipated to decrease to $0.21 per share as operational accretion partially offsets annualized financing costs. JNJ will incorporate these estimates into its full-year 2025 financial outlook during first quarter results announcement on April 15, 2025. Following the acquisition, Intra-Cellular Therapies will delist from NASDAQ.
Johnson & Johnson (NYSE: JNJ) ha annunciato piani per completare l'acquisizione di Intra-Cellular Therapies intorno al 2 aprile 2025, dopo l'approvazione degli azionisti il 27 marzo 2025. Si prevede che la transazione aumenterà la crescita delle vendite di JNJ nel 2025 del 0,8%, aggiungendo circa 0,7 miliardi di dollari in vendite incrementali.
L'acquisizione dovrebbe diluire l'utile per azione rettificato (EPS) di 0,25 dollari nel 2025, un miglioramento rispetto alla precedente stima di una diluizione di 0,30-0,35 dollari. Per il 2026, si prevede che la diluizione degli utili scenderà a 0,21 dollari per azione, poiché l'accrezione operativa compenserà parzialmente i costi di finanziamento annualizzati. JNJ integrerà queste stime nella sua previsione finanziaria per l'intero anno 2025 durante l'annuncio dei risultati del primo trimestre il 15 aprile 2025. Dopo l'acquisizione, Intra-Cellular Therapies verrà rimossa dal NASDAQ.
Johnson & Johnson (NYSE: JNJ) ha anunciado planes para completar su adquisición de Intra-Cellular Therapies alrededor del 2 de abril de 2025, tras la aprobación de los accionistas el 27 de marzo de 2025. Se prevé que la transacción impulse el crecimiento de ventas de JNJ en 2025 en un 0,8%, añadiendo aproximadamente 0,7 mil millones de dólares en ventas incrementales.
Se espera que la adquisición diluya las ganancias ajustadas por acción (EPS) en 0,25 dólares en 2025, una mejora respecto a la estimación previa de dilución de 0,30-0,35 dólares. Para 2026, se anticipa que la dilución de ganancias disminuya a 0,21 dólares por acción, ya que la acumulación operativa compensará parcialmente los costos de financiamiento anualizados. JNJ incorporará estas estimaciones en su perspectiva financiera para todo el año 2025 durante el anuncio de resultados del primer trimestre el 15 de abril de 2025. Tras la adquisición, Intra-Cellular Therapies será eliminada de NASDAQ.
존슨앤존슨 (NYSE: JNJ)은 인트라셀룰러 테라피스 인수 완료 계획을 2025년 4월 2일경으로 발표했으며, 2025년 3월 27일 주주 승인 후 진행될 예정입니다. 이 거래는 JNJ의 2025년 매출 성장률을 0.8% 증가시킬 것으로 예상되며, 약 7억 달러의 추가 매출을 더할 것입니다.
이번 인수로 인해 2025년 조정 주당순이익(EPS)이 0.25달러 감소할 것으로 예상되며, 이는 이전에 추정된 0.30-0.35달러의 감소보다 개선된 수치입니다. 2026년에는 운영적 증가가 연간 금융 비용을 부분적으로 상쇄하여 주당 0.21달러로 감소할 것으로 예상됩니다. JNJ는 2025년 1분기 실적 발표인 2025년 4월 15일에 이러한 추정치를 전체 연도 2025년 재무 전망에 포함시킬 것입니다. 인수 후, 인트라셀룰러 테라피스는 NASDAQ에서 상장 폐지될 것입니다.
Johnson & Johnson (NYSE: JNJ) a annoncé des plans pour finaliser son acquisition de Intra-Cellular Therapies aux alentours du 2 avril 2025, après l'approbation des actionnaires le 27 mars 2025. La transaction devrait augmenter la croissance des ventes de JNJ en 2025 de 0,8%, ajoutant environ 0,7 milliard de dollars en ventes supplémentaires.
On s'attend à ce que l'acquisition dilue le bénéfice par action ajusté (EPS) de 0,25 dollar en 2025, une amélioration par rapport à l'estimation précédente de dilution de 0,30-0,35 dollar. Pour 2026, la dilution des bénéfices devrait diminuer à 0,21 dollar par action, car l'accroissement opérationnel compensera partiellement les coûts de financement annualisés. JNJ intégrera ces estimations dans ses prévisions financières pour l'année 2025 lors de l'annonce des résultats du premier trimestre le 15 avril 2025. Suite à l'acquisition, Intra-Cellular Therapies sera retirée du NASDAQ.
Johnson & Johnson (NYSE: JNJ) hat Pläne angekündigt, die Übernahme von Intra-Cellular Therapies um den 2. April 2025 abzuschließen, nachdem die Aktionäre am 27. März 2025 zugestimmt haben. Es wird erwartet, dass die Transaktion das Umsatzwachstum von JNJ im Jahr 2025 um 0,8% steigern wird, was etwa 0,7 Milliarden Dollar an zusätzlichen Verkäufen hinzufügt.
Die Übernahme wird voraussichtlich das bereinigte Ergebnis je Aktie (EPS) im Jahr 2025 um 0,25 Dollar verwässern, was eine Verbesserung gegenüber der zuvor geschätzten Verwässerung von 0,30-0,35 Dollar darstellt. Für 2026 wird erwartet, dass die Ergebnisverwässerung auf 0,21 Dollar pro Aktie sinkt, da die betriebliche Akquisition die jährlichen Finanzierungskosten teilweise ausgleicht. JNJ wird diese Schätzungen in seine Finanzprognose für das Gesamtjahr 2025 während der Bekanntgabe der Ergebnisse des ersten Quartals am 15. April 2025 einbeziehen. Nach der Übernahme wird Intra-Cellular Therapies von der NASDAQ gestrichen.
- Sales growth acceleration of 0.8% expected in 2025
- Incremental sales of $0.7 billion anticipated
- Improved EPS dilution impact from initial estimates ($0.25 vs $0.30-$0.35)
- Expected reduction in earnings dilution by 2026
- EPS dilution of $0.25 expected in 2025
- Continued earnings dilution of $0.21 per share projected for 2026
The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by approximately
Following the completion of the transaction, Intra-Cellular Therapies’ common stock will cease trading on the NASDAQ Global Select Market.
This release corrects a prior statement that the closing had occurred.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com/ or at www.innovativemedicine.jnj.com. Follow us at @JNJInnovMed.
CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS:
- This press release contains “forward-looking statements” regarding the acquisition of Intra-Cellular Therapies by Johnson & Johnson and CAPLYTA® and development programs. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson or Intra-Cellular Therapies.
- Risks and uncertainties include, but are not limited to: the completion of the acquisition in the expected timeframe; challenges inherent in product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new products; manufacturing difficulties and delays; product efficacy or safety concerns resulting in product recalls or regulatory action; economic conditions, including currency exchange and interest rate fluctuations; the risks associated with global operations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; changes to applicable laws and regulations, including tax laws and global health care reforms; adverse litigation or government action; changes in behavior and spending patterns or financial distress of purchasers of health care services and products; and trends toward health care cost containment.
- In addition, there will be risks and uncertainties related to the ability of the Johnson & Johnson family of companies to successfully integrate the programs, products, technologies and employees/operations and clinical work of Intra-Cellular Therapies. A further list and description of these risks, uncertainties and other factors and the general risks associated with the respective businesses of Johnson & Johnson and Intra-Cellular Therapies can be found in Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended December 29, 2024, filed with the SEC on February 13, 2025, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent filings with the SEC and in Intra-Cellular Therapies’ Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the SEC on February 21, 2025, including in the sections captioned “Cautionary Statement Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Intra-Cellular Therapies’ subsequent filings with the SEC. Copies of these filings, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com, www.intracellulartherapies.com, or on request from Johnson & Johnson or Intra-Cellular Therapies.
- Neither Johnson & Johnson nor Intra-Cellular Therapies undertakes to update any forward-looking statement as a result of new information or future events or developments, except as required by law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250401997629/en/
Johnson & Johnson
Media Contact:
media-relations@its.jnj.com
Investor Contact:
investor-relations@its.jnj.com
Source: Johnson & Johnson
FAQ
When will Johnson & Johnson (JNJ) complete the Intra-Cellular Therapies acquisition?
How much will the Intra-Cellular acquisition impact JNJ's 2025 sales growth?
What is the expected EPS dilution impact of JNJ's Intra-Cellular acquisition in 2025?
How will the Intra-Cellular acquisition affect JNJ's earnings in 2026?
